Boston, MANCT06691217Now EnrollingIRB Ready

Vascular Inflammation Clinical Trial in Boston, MA

Access cutting-edge vascular inflammation treatment through this clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by Massachusetts General Hospital

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access vascular inflammation specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related vascular inflammation treatment provided free

Apply for This Boston Location

Check if you qualify for this vascular inflammation clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Vascular Inflammation Study in Boston

The primary goal of this clinical trial is to test the hypothesis that the drug canakinumab (anti-IL-1B monoclonal antibody) decreases vascular inflammation when used by people with a history of coronary artery disease, including those with and without clonal hematopoiesis driven by mutations in TET2.

Sponsor: Massachusetts General Hospital

Who Can Participate

Inclusion Criteria

18 years or older
Coronary artery disease, defined as prior heart attack, coronary stent procedure \>180 days before baseline imaging, or advanced subclinical coronary atherosclerosis (coronary artery calcium score ≥300 Agatston units, CAD-RADS 3 or greater atherosclerosis on coronary CT angiography, or qualitatively severe coronary artery calcification identified on non-gated CT imaging)
Presence of either TET2 mutations or no myeloid driver mutations on prior sequencing

Exclusion Criteria

placement of a drug-eluting stent in a proximal coronary arterial segment \<180 days before baseline imaging
prior coronary artery bypass grafting
pregnancy or breastfeeding
history of blood malignancy or current solid-tumor malignancy
history of organ or stem cell transplantation
current treatment with prescription, systemic (oral, IV \[intravenous\], or IM \[intramuscular\]) steroids or anti-inflammatory/immune suppressant medical therapies (including colchicine but excluding topical therapies, UV therapy, ASA-derivative therapies, or NSAIDS) for autoimmune/inflammatory diseases, post-transplant care, asthma, or pain
use of oral steroids or prescription oral anti-inflammatory/immune suppressant medication for \>7 days within the past 1 month
use of IV or IM steroids or IV or IM anti-inflammatory/immune suppressant medication within the past 3 months
known allergy to dextran's and/or DTPA and/or radiometals and/or severe allergy to iodinated contrast media
estimated glomerular filtration rate (eGFR) \< 45 ml/min/1.73 m2
contraindications to nitroglycerin known narrow angle glaucoma, or known severe aortic stenosis
use of phosphodiesterase type 5 inhibitor AND refusal to abstain from use of these medications within the 5 days prior to scheduled CCTA scan
significant radiation exposure (40msV) received within the past 12 months
concurrent enrollment in another research study judged by the investigators to interfere with the current study
known active or recurrent hepatic disease (including cirrhosis or ALT/AST levels \>3 times the upper limit oof or total bilirubin \>2 times the upper limits of normal)
history or evidence of tuberculosis (TB) (active or latent) infection or risk factor for TB
active bacterial, fungal or viral infection at the time of enrollment or history of recurrent infections
suspected or proven immunocompromised state
live vaccinations within 3 months prior to randomization visit or live vaccinations planned during the trial

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT06691217) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Vascular Inflammation Treatment Options in Boston, MA

If you're searching for vascular inflammation treatment options in Boston, MA, this clinical trial (NCT06691217) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced vascular inflammation specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all vascular inflammation clinical trials near you to find additional studies recruiting in your area.

More Multiple Myeloma Trials in Boston, MA

See all multiple myeloma clinical trials recruiting in Boston — not just this study.

Browse Multiple Myeloma Trials in Boston →

Browse More Trials by Condition

Multiple Myeloma TrialsFollicular Lymphoma TrialsAnkylosing Spondylitis TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA